Efficacy and safety of alirocumab in Japanese subjects (Phase 1 and 2 Studies)

American Journal of Cardiology

Volumn 118, Issue 1, 2016, Pages 56-63

  Teramoto, Tamio ^a   Kobayashi, Masahiko ^b   Uno, Kiyoko ^b   Takagi, Yoshiharu ^b   Matsuoka, Osamu ^c   Sugimoto, Masayuki ^d   Inoue, Satoshi ^e   Minami, Fumiko ^f   Baccara Dinet, Marie Thérèse ^g  

^a Teikyo Academic Research Center   (Japan)

^b Sanofi ^*  (Japan)

^c ToCROM Clinic   (Japan)

^d Koganeibashi Sakura Clinic   (Japan)

^e Heishinaki Medical Group Incorporated   (Japan)

^f Daiwa   (Japan)

^g SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALANINE PHOSPHATASE; ALIROCUMAB; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATASE; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; JAPANESE (PEOPLE); MALE; ORTHOSTATIC HYPOTENSION; PARALLEL DESIGN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; JAPAN; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; JAPAN; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84966716431     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2016.04.011     Document Type: Conference Paper

References (26)

1. H. Imano, H. Noda, A. Kitamura, S. Sato, M. Kiyama, T. Sankai, T. Ohira, M. Nakamura, K. Yamagishi, A. Ikeda, T. Shimamoto, and H. Iso Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: the Circulatory Risk in Communities Study (CIRCS) Prev Med 52 2011 381 386
2. P.W. Wilson, R.B. D'Agostino, D. Levy, A.M. Belanger, H. Silbershatz, and W.B. Kannel Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847
3. M. Matsuzaki, T. Kita, H. Mabuchi, Y. Matsuzawa, N. Nakaya, S. Oikawa, Y. Saito, J. Sasaki, K. Shimamoto, H. Itakura, and J-LIT Study Group. Japan Lipid Intervention Trial Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia Circ J 66 2002 1087 1095
4. H. Mabuchi, T. Kita, M. Matsuzaki, Y. Matsuzawa, N. Nakaya, S. Oikawa, Y. Saito, J. Sasaki, K. Shimamoto, H. Itakura, and J-LIT Study Group. Japan Lipid Intervention Trial Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT) Circ J 66 2002 1096 1100
5. T. Okamura, H. Tanaka, N. Miyamatsu, T. Hayakawa, T. Kadowaki, Y. Kita, Y. Nakamura, A. Okayama, H. Ueshima, and NIPPON DATA80 Research Group The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort Atherosclerosis 190 2007 216 223
6. J. Stamler, M.L. Daviglus, D.B. Garside, A.R. Dyer, P. Greenland, and J.D. Neaton Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity JAMA 284 2000 311 318
7. Y. Nakamura, T. Yamamoto, T. Okamura, T. Kadowaki, T. Hayakawa, Y. Kita, S. Saitoh, A. Okayama, H. Ueshima, and NIPPON DATA80 Research Group Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980-1994 Circ J 70 2006 960 964
8. Y. Hata, H. Mabuchi, Y. Saito, H. Itakura, G. Egusa, H. Ito, T. Teramoto, M. Tsushima, N. Tada, S. Oikawa, N. Yamada, S. Yamashita, N. Sakuma, and J. Sasaki Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults J Atheroscler Thromb 9 2002 1 27
9. T. Teramoto, J. Sasaki, H. Ueshima, G. Egusa, M. Kinoshita, K. Shimamoto, H. Daida, S. Biro, K. Hirobe, T. Funahashi, K. Yokote, and M. Yokode Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese J Atheroscler Thromb 14 2007 45 50
10. T. Teramoto, J. Sasaki, S. Ishibashi, S. Birou, H. Daida, S. Dohi, G. Egusa, T. Hiro, K. Hirobe, M. Iida, S. Kihara, M. Kinoshita, C. Maruyama, T. Ohta, T. Okamura, S. Yamashita, M. Yokode, K. Yokote, and Japan Atherosclerosis Society Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version J Atheroscler Thromb 20 2013 517 523
11. T. Teramoto, A. Kashiwagi, H. Mabuchi, and J.L. Investigators Status of lipid-lowering therapy prescribed based on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults: a study of the Japan Lipid Assessment Program (J-LAP) Curr Ther Res Clin Exp 66 2005 80 95
12. T. Teramoto, K. Kokubo, and S. Yatsunami Epidemiological studies of cholesterol management by statin treatment in 2012 edition of atherosclerotic cardiovascular disease prevention guidelines Jpn Pharmacol Ther 41 2013 415 424
13. E.M. Roth, M.R. Taskinen, H.N. Ginsberg, J.J. Kastelein, H.M. Colhoun, J.G. Robinson, L. Merlet, R. Pordy, and M.T. Baccara-Dinet Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial Int J Cardiol 176 2014 55 61
14. C.P. Cannon, B. Cariou, D. Blom, J.M. McKenney, C. Lorenzato, R. Pordy, U. Chaudhari, H.M. Colhoun, and ODYSSEY COMBO II Investigators Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial Eur Heart J 36 2015 1186 1194
15. H. Bays, D. Gaudet, R. Weiss, J.L. Ruiz, G.F. Watts, I. Gouni-Berthold, J. Robinson, J. Zhao, C. Hanotin, and S. Donahue Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I Randomized Trial J Clin Endocrinol Metab 100 2015 3140 3148
16. D.J. Kereiakes, J.G. Robinson, C.P. Cannon, C. Lorenzato, R. Pordy, U. Chaudhari, and H.M. Colhoun Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study Am Heart J 169 2015 906 915 e913
17. J.J. Kastelein, H.N. Ginsberg, G. Langslet, G.K. Hovingh, R. Ceska, R. Dufour, D. Blom, F. Civeira, M. Krempf, C. Lorenzato, J. Zhao, R. Pordy, M.T. Baccara-Dinet, D.A. Gipe, M.J. Geiger, and M. Farnier ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia Eur Heart J 36 2015 2996 3003
18. E.M. Roth, J.M. McKenney, C. Hanotin, G. Asset, and E.A. Stein Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
19. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
20. J.G. Robinson, M. Farnier, M. Krempf, J. Bergeron, G. Luc, M. Averna, E.S. Stroes, G. Langslet, F.J. Raal, M. El Shahawy, M.J. Koren, N.E. Lepor, C. Lorenzato, R. Pordy, U. Chaudhari, J.J. Kastelein, and ODYSSEY LONG TERM Investigators Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N Engl J Med 372 2015 1489 1499
21. E.A. Stein, D. Gipe, J. Bergeron, D. Gaudet, R. Weiss, R. Dufour, R. Wu, and R. Pordy Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
22. J.G. Robinson, H.M. Colhoun, H.E. Bays, P.H. Jones, Y. Du, C. Hanotin, and S. Donahue Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies Clin Cardiol 37 2014 597 604
23. D. Gaudet, D.J. Kereiakes, J.M. McKenney, E.M. Roth, C. Hanotin, D. Gipe, Y. Du, A.C. Ferrand, H.N. Ginsberg, and E.A. Stein Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials) Am J Cardiol 114 2014 711 715
24. D.J. Rader, W.A. Mann, W. Cain, H.G. Kraft, D. Usher, L.A. Zech, J.M. Hoeg, J. Davignon, P. Lupien, M. Grossman, J.M. Wilson, and H.B. Brewer Jr. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans J Clin Invest 95 1995 1403 1408
25. K. Shioji, M. Izuhara, H. Mitsuoka, T. Uegaito, M. Matsuda, and Kishiwada Atherosclerosis Prevention Study Group Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin Cardiovasc Ther 32 2014 97 104
26. A. Hirayama, N. Honarpour, M. Yoshida, S. Yamashita, F. Huang, S.M. Wasserman, and T. Teramoto Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk Circ J 78 2014 1073 1082